Javier Valdivia

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: Lurbinectedin was active as second-line therapy for SCLC in terms of overall response and had an acceptable and manageable safety profile.

TL;DR: There was no improvement in efficacy with talactoferrin alfa in patients with advanced NSCLC whose disease had failed two or more prior regimens and the safety profiles were comparable between arms.

TL;DR: The BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible and it is expected that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches.

TL;DR: EGFR TKIs (gefitinib and erlotinib) are used as the preferred first-line treatment while chemotherapy is more frequently administered as a second- and third-line option in routine clinical practice in Spain.